Symbol="PRLD"
AssetType="Common Stock"
Name="Prelude TherapeuticsÂ Inc"
Description="Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized to target key drivers in cancers. The company is headquartered in Wilmington, Delaware."
CIK="1678660"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="200 POWDER MILL ROAD, WILMINGTON, DE, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="183061000"
EBITDA="-124046000"
PERatio="None"
PEGRatio="None"
BookValue="4.788"
DividendPerShare="0"
DividendYield="0"
EPS="-2.33"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.29"
ReturnOnEquityTTM="-0.464"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-2.33"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="9.4"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="1.145"
EVToRevenue="-"
EVToEBITDA="-0.214"
Beta="0.328"
num_52WeekHigh="8.66"
num_52WeekLow="3.17"
num_50DayMovingAverage="4.322"
num_200DayMovingAverage="5.72"
SharesOutstanding="41958500"
DividendDate="None"
ExDividendDate="None"
symbol="PRLD"
open="3.34"
high="3.48"
low="3.17"
price="3.44"
volume="463532.00"
latest_trading_day="2023-08-23"
previous_close="3.30"
change="0.14"
change_percent="4.2424%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="67"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="33"
Volume_recent_avg="115026"
Change_recent_avg="-0.02"
Delta_recent_avg="0.43"
Variance_recent_avg="0.21"
Change_ratio_recent_avg="-0.62"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="33"
Aroon_momentum_negative="67"
image_negative_thumbnail_id_1="1117"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0150.jpeg"
image_negative_thumbnail_id_2="130"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0046.jpeg"
image_neutral_thumbnail_id_1="546"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0053.jpeg"
image_neutral_thumbnail_id_2="591"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0008.jpeg"
image_positive_thumbnail_id_1="988"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0150.jpeg"
image_positive_thumbnail_id_2="628"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0080.jpeg"
image_professor_thumbnail_id_1="1193"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0027.jpeg"
image_professor_thumbnail_id_2="1184"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0018.jpeg"
